JAN 25, 2018 10:00 AM PST

WEBINAR: Engineered Viruses as Precision Cancer Therapeutics


Abstract

DATE: January 25, 2018
TIME: 10:00am PST, 1:00pm EST, 6:00pm GMT

Oncolytic virotherapy, the use of viral vectors to treat cancer, holds huge promise. Viruses are natural DNA delivery vehicles evolved to target specific tissues and transform them. Oncolytic virotherapies harness these abilities for therapeutic rather than pathological results. By engineering the virus to target cancerous cells rather than healthy cells we can create virotherapies which self-amplify at the point of need. Whilst historically safety focused, the field has now pivoted to enhanced efficacy following the first approved oncolytic virotherapy, T-VEC, for melanoma.

Our laboratory develops Adenoviruses (Ads) as oncolytics. Ads are versatile platforms offering large transgene capacity, ease of manipulation, and lytic potential with an excellent safety profile. However, current Ad-based therapies are hampered by high levels of pre-existing immunity within the population and off-target effects caused by the promiscuity of Ads’ canonical receptor: CAR.

We address these issues by a “bottom up” engineering approach to enhance the well characterised Ad5 serotype combined with a “top down” investigation of understudied Adenoviruses with advantageous phenotypes. By engineering Ad5 we can ablate natural tropism and facilitate specific infection of cancer cells; demonstrated by both in vitro, and in vivo models of cancer. Concurrently, we can develop rare Adenovirus serotypes devoid of pre-existing immunity, namely neutralising antibody activity. Integrating proteins from these serotypes into therapeutic vectors enables us to radically improve cancer cell transduction.

Once targeted, the viruses must be capable of efficient cancer cell killing. We have developed Ad vectors with a variety of transgenes to manipulate signalling pathways for therapeutic benefit. Current research focuses on combining the above aptitudes into a single virus with a 3-pronged therapeutic action:

• Inherent viral immunogenicity

• Direct cancer cell lysis

• Stimulation of anti-tumour immunity

 

Key Learning Objectives:

  • Understand how protein engineering can be used to generate tissue specific viruses.
  • Learn how re-engineered viruses can be used as cancer therapies.

Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
JUL 28, 2021 8:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUL 28, 2021 8:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: July 28, 2021 Time: 8:00am PDT Breast cancer is the most common form of cancer in women. It is estimated that 1 out of 8 women in the US will develop invasive breast cancer during her...
JAN 25, 2018 10:00 AM PST

WEBINAR: Engineered Viruses as Precision Cancer Therapeutics


Specialty

Cancer Research

Biotechnology

Cell Biology

Immunology

Molecular Biology

Cancer Therapeutics

Cancer Diagnostics

Cell Culture

Genetics

Molecular Diagnostics

Biomarkers

Microbiology

Clinical Research

Biochemistry

Clinical Chemistry

Geography

North America55%

Europe23%

Asia12%

South America5%

Africa2%

Oceania1%

Registration Source

Website Visitors86%

Email Promotions6%

WAVE Newsletter Promotion6%

Social Media Promotions1%

Website Banners1%

Job Title

Student19%

Research Scientist13%

Medical Laboratory Technician11%

Scientist9%

Educator/Faculty8%

Facility/Department Manager8%

Executive8%

Lab Management5%

Medical Doctor/Specialist5%

Post Doc4%

Clinical Laboratory Scientist4%

Biologist2%

QC/QA2%

Microbiologist2%

Consultant1%

Chemist1%

Organization

Academic Institution15%

Clinical Laboratory8%

Biotech Company6%

Research Institute6%

Hospital5%

Life Science Company3%

Medical School2%

Ambulatory Care2%

Pharmaceutical Company2%

Medical Center2%

Government2%

Non-Profit Organization2%

Industrial Company1%

Consultant1%

Other4%


Show Resources
Loading Comments...
Show Resources
Attendees
  • See more